This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Aegerion Pharmaceuticals Inc (AEGR)

NASDAQ: Health Care

Company Cash Flow
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Cash Flow From Operating Activities
Net Income (Loss) -63.36M -62.26M 0.00 -14.25M
Operating Gains/Losses 0.00 766.00K 0.00 0.00
Extraordinary Gains / Losses 0.00 0.00 0.00 0.00
(Increase) Decrease In Receivables -7.57M 0.00 0.00 0.00
(Increase) Decrease in Inventories -1.59M 0.00 0.00 0.00
(Increase) Decrease In Other Current Assets 0.00 0.00 0.00 0.00
(Decrease) Increase In Payables -1.12M 2.15M -347.30K 1.73M
(Decrease) Increase In Other Current Liabilities 8.21M 4.22M 3.21M 277.74K
(Increase) Decrease In Other Working Capital 44.00K 11.00K -171.52K 0.00
Other Non-Cash Items 28.17M 11.98M -33.19M 4.20M
Net Cash From Continuing Operations -38.38M -42.56M -30.51M -8.50M
Net Cash From Discontinued Operations 0.00 0.00 0.00 0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities -38.38M -42.56M -30.51M -8.50M
Sale of Property, Plant & Equipment 0.00 0.00 0.00 0.00
Cash Used for Investing Activities
Sale of Short-Term Investments 2.19M 2.26M 16.91M 0.00
Purchases of Property, Plant & Equipment -716.00K -815.00K -631.31K -11.72K
Acquisitions 0.00 0.00 0.00 0.00
Purchases of Short-Term Investments -77.91M -54.42M -62.81M 0.00
Other Cash from Investing Activities 0.00 0.00 0.00 0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities -22.80M -28.00K -46.53M -11.72K
Issuance of Debt 0.00 10.61M 10.00M 7.50M
Cash Used for Financing Activities
Issuance of Capital Stock 88.06M 53.72M 49.58M 50.80M
Repayment of Long-Term Debt 0.00 -10.88M 0.00 -5.48M
Repurchase of Capital Stock 0.00 0.00 0.00 0.00
Payment of Cash Dividends 0.00 0.00 0.00 0.00
Other Financing Charges, Net -3.02M -75.00K -243.55K -1.64M
Net Cash From Financing Activities 85.04M 53.38M 59.33M 51.18M
Effect of Exchange Rate Changes -14.00K 8.00K -24.86K 0.00
Net Change in Cash & Cash Equivalents 23.84M 10.80M -17.73M 42.67M
AEGR News

AEGR Aegerion Pharmaceuticals Inc

Analysts Ratings for AEGR

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 7 7 7 8
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET AEGR ANALYST REPORT

Brokerage Partners

AEGR Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs